Reduced-toxicity conditioning with fludarabine and treosulfan is a dose-intensive regimen with enhanced anti-leukemia effect and acceptable toxicity in AML/MDS. HLA-C regulates naturalkiller (NK) cell function by inhibiting Killer immunoglobulin-like receptors (KIR) and is divided into C1 and C2 epitopes. The missing-ligand theory suggests that missing recipient KIR ligands drives NK-alloreactivity after SCT, in the absence of HLA-mismatch by activating unlicensed donor NK cells. We analyzed SCT outcomes in 203 patients with AML/MDS, median age 58 years, given SCT from matched-siblings (n 5 97) or matched-unrelated donors (n 5 106), using two treosulfan doses (total 36 or 42 g/m 2 ). 34% expressed one HLA-C group 1 allele (C1C1), 19% one HLA-C group 2 allele (C2C2), and 48% both KIR ligands (C1C2). Median follow-up was 48 months. 5-year relapse, nonrelapse mortality (NRM) and leukemia-free survival (LFS) rates were 38%, 27%, and 36%, respectively. Relapse rates were 43%, 45%, and 26% in patients expressing C1C1, C1C2, and C2C2 ligands, respectively (P 5 .03). Multivariate-analysis identified chemo-refractory disease (HR 3.1, P 5 .003), poor cytogenetics (HR 1.7, P 5 .08), female donor to male recipient (HR 0.4, P 5 .01) and C2C2 ligands (HR 0.4, P 5 .04) as independent factors predicting relapse. HLA-C ligands were not associated with GVHD or NRM. LFS was 33%, 30%, and 46%, respectively (P 5 .07). Chemorefractory disease (HR 3.1, P 5 .0004) and C2C2 group ligand (HR 0.6, P 5 .06) independently predicted LFS. Treosulfan dose did not predict any SCT outcome. In conclusion, missing HLA-C group 1 ligand is associated with reduced relapse risk, similar NRM and improved LFS, after HLA-matched SCT with treosulfan conditioning in AML/MDS.
These properties make treosulfan an attractive candidate for the use in conditioning regimens prior to allogeneic SCT.
The combination of fludarabine and treosulfan (FT) has been introduced over the last few years. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It was reported mostly in patients with AML and MDS, [10] [11] [12] [13] [14] [15] but also in lymphoid malignancies, 16 acute lymphoblastic leukemia and in pediatric patients. 17 However all adult series were based on relatively small patient groups (26-85 patients per study) and further refining of treatment schedule is still indicated.
FT can be defined as an RTC regimen sharing some of the characteristics of MAC and some of RIC. Similar to MAC it is associated with rapid achievement of full donor chimerism and a relatively low relapse rate.
Similar to RIC it is associated with lesser degree of mucositis and organ toxicities and a lower incidence of acute GVHD. Thus it may better balance the risks and benefits of intensive conditioning.
Natural killer (NK) cells are an essential part of the innate immune system directed against malignancy and infections. 18 is specific for group C2, while KIR2DL2/3 is specific for group C1. donor, and transplant characteristics. 18, 19 In this study we explored the outcome following FT in a relatively large series of patients with AML and MDS. We focused on the relative outcomes related to different treosulfan doses. We also investigated prognostic factors for SCT outcomes. In particular, we explored the role KIR ligand group typing may have in this SCT setting.
| P A T I E NT S A ND M E T H O DS

| Patient eligibility
The study included a retrospective analysis of 203 patients with AML and MDS given FT conditioning and allogeneic SCT in two institutions, Chaim Sheba Medical Center (ClinicalTrial.gov NCT00491634) and San
Raffaele Scientific Institute (Allo-Treo, Eudract 2005-005182-11).
Some of the patients were included in previous publications. 11, 12 Patients with AML were eligible for allogeneic SCT if they had AML in first complete remission (CR1) at high-risk for disease relapse due to adverse cytogenetic or molecular characteristics according to the European LeukemiaNet criteria, a high white blood cell count at presenta- according to HLA typing as previously described. 22 Patient and donor KIR genotyping was not available. All patients were treated according to protocols that were approved by the institution review-board and gave written informed consent for their intended protocol.
| Conditioning regimens
All patients were given fludarabine and treosulfan conditioning. on days 3 and 6). GVHD prophylaxis was administered for 3-6 months and tapered afterwards in patients with no active GVHD. GVHD prophylaxis did not differ between the two centers. G-CSF was administered in all patients from day 17 until engraftment, by institutional guidelines.
Similar standard institutional regimen of antibiotic prophylaxis were used to prevent bacterial, viral, fungal, and Pneumocystis carini infections.
| Evaluation of outcomes
Neutrophil and platelet engraftment were defined as the first of 3 days with absolute neutrophil count (ANC) >0. 
| Statistical analysis
The primary end point of the study was 5-year leukemia-free survival (LFS). Secondary endpoints included nonrelapse mortality (NRM), relapse incidence, overall survival (OS), acute and chronic GVHD.
Patient characteristics were compared between groups by the Chisquare method for qualitative variables, and Mann-Whitney test for continuous parameters. OS was calculated from the day of SCT until death or last follow-up. LFS was calculated from the day of SCT until death, relapse or last follow-up. The probability of OS and LFS was estimated using the Kaplan-Meier method. 23 Relapse and NRM rates were estimated using cumulative incidence analysis and considered as competing risks. 24 Patients with no event were censored at last contact. In the analysis of the cumulative incidence of GVHD, relapse and death were considered competing risks. For all prognostic analyses, continuous variables were categorized and the median used as a cut-off point. The effect of various patient and disease categorical variables on survival probabilities was studied with the log-rank test.
Cumulative incidence rates were compared by Gray test. All rates are presented with 95% confidence intervals. Multivariable analyses were performed using Cox proportional hazards model. All P values are two-sided and values <0.05 were considered statistically significant.
Statistical analyses were performed with SPSS 21.0 (Chicago) and R2.14.2 software packages (R Development Core Team, Vienna, Austria).
| R E S U L T S 3.1 | Patient and donor characteristics
The study included 203 patients with AML (n 5 129) and MDS (n 5 74)
following allogeneic SCT with treosulfan-based conditioning in 2 institutions. One-hundred and twenty-three patients were given FT12 conditioning in one institution while 80 patients were given FT14 conditioning in the second. The two institutions shared similar patient selection and supportive care approaches. Patient characteristics are The FT12 recipients were older than FT14 recipients (59 vs. 52
years, respectively, P < .001). A lower proportion of FT12 recipients were in CR1 and more were in refractory or previously untreated status at SCT. More FT12 patients had adverse cytogenetic or molecular markers. ATG was given more often during FT12 conditioning.
KIR ligand typing was determined from high-resolution HLA typing. There was no difference between the Israeli and Italian populations. HLA C1C1, C1C2 and C2C2 were seen in 34%, 48% and 19% of the patients, respectively. Bw4 was expressed in 67% of all patients.
There was no difference between patients with and without mismatch in the C ligand typing. However, in three patients the C mismatch caused NK allo-reactivity according to the missing-self model (the host lacked a C ligand type that was present in the donor).
| Engraftment and chimerism
One-hundred and eighty-five patients achieved primary engraftment. There was no significant difference in chimerism kinetics. At one month after SCT, 89% of FT12 recipients and 92% of FT14 recipients had complete donor chimerism (>95% donor), P 5 .69. Similarly, there was no difference between the regimens in chimerism at 3 months after SCT.
| GVHD and nonrelapse mortality
The cumulative incidence rate of acute GVHD grades II-IV was 22%
(95% CI, 16-31%) and 39% (95% CI, 29-52%) after FT12 and FT14, respectively (P 5 .01). The cumulative incidence rates of acute GVHD grade III-IV were 10% (95% CI, 6-18%), and 16% (95% CI, 9-28%), respectively (P 5 .13). The cumulative incidence of chronic GVHD was similar, 44% (95% CI, 34-57) and 36% (95% CI, 29-46), respectively (P 5 .96).
NRM occurred in 51 patients with a cumulative incidence of 27% (95% C.I. 21-34%) at 5 years after SCT. Eight patients died of organ toxicities, 2 of intracranial bleeding, 13 patients died of complications related to GVHD, 22 died of infections, 3 of graft failure, 2 of secondary malignancy, and 1 of suicide. There was also a trend for a higher incidence in older patients and patients with comorbidities. The multivariate analysis determined that disease status was the only independent factors predicting NRM ( Table   3 ). The KIR ligand groups had no impact on NRM (Tables 2 and 3 ; Figure 1a ).
| Relapse
Sixty-six patients relapsed after SCT, with a cumulative incidence of Figure 1b) . The multivariate analysis determined that chemorefractory disease (HR 3.1, P 5 .003), adverse cytogenetics (HR 1.7, P 5 .08), female donor to male recipient (HR 0.4, P 5 .01) and C2C2 KIR ligand group (HR 0.4, P 5 .04) were independent factors predicting relapse (Table 3 ). The advantage in relapse for the C2C2 group was limited to early relapses within the first 6 months after transplant. Early relapses occurred in 23%, 28%, and 10% in the C1C1, C1C2, and C2C2 groups, respectively (P 5 .04). In contrast, in patients alive and leukemia free more than 6 months after SCT, subsequent relapse rates were not statistically different between the C ligand groups 31, 31, and 21%, respectively (P 5 .29).
| Outcome
With a median follow-up of 48 months (6-108), 86 patients are alive and leukemia-free. The 5-year LFS and OS rates were 36% (95% CI 28-43%) and 39% (95% CI 32-47%, Supporting Information Figure   1a ), respectively. There was a statistically significant advantage in LFS with FT14. The 5-year LFS rate was 30% (95% CI, 21-39%) after FT12
and 44% (95% CI, 33-56) after FT14, respectively (P 5 .05, Supporting
Information Figure 1b) . Disease status was the most significant factor predicting LFS with highest rates in patients in CR1 and the lowest rates in refractory disease at SCT (Supporting Information Figure 1c , P < .001). LFS was lower in patients with comorbidities (P 5 .07).
Patients with C2C2 KIR ligand group had a LFS rate of 46% (95% CI, 27-65), that was higher than the rate in patients with C1C1 [33% (95% CI, 18-48)] and C1C2 [30% (95% CI, 19-40), P 5 .07, Figure 1c ].
The multivariate analysis determined that chemo-refractory disease (HR 3.1, P 5 .0004), and C2C2 KIR ligand group (HR 0.6, P 5 .06) were independent factors predicting LFS (Table 3 ). The same factors predicted for OS (data not shown). The survival advantage related to the C2C2 ligand group was seen in patients with AML but was not apparent in the MDS subgroup (data not shown). Similarly, survival advantage was seen in the group of patients given ATG during conditioning. 5-year LFS was 51%, 40%, and 30% in patients with C2C2, C1C1, and C1C2 KIR ligand group respectively (P 5 .10). In a multivariate analysis limited to ATG recipients, the HR for LFS for C2C2 was 0.5 (P 5 .08). Among patients not given ATG the LFS rates were similar, Tables 1 and 2 . HR, hazard ratio.
FIG URE 1
Outcomes after stem cell transplantation according to KIR ligand group. Relapse incidence (A), nonrelapse mortality (B), leukemia-free survival (C) 33%, 27%, and 30%, respectively (P 5 .56). However, this analysis is based on small patient numbers. Other subset analyses were not feasible due to low patient numbers.
| DISCUSSION
In the current study we explored the predicting factors for posttransplantation outcomes after treosulfan-based conditioning. This regimen was associated with a relatively low NRM in a relatively highrisk older population with mostly advanced AML and MDS. As previously reported treosulfan is associated with a low-risk for acute GVHD and organ toxicity. , there was no difference in NRM with increasing dose. 9 Similarly, in a large retrospective analysis of 193 children reported to EBMT, there was relatively low rate of NRM, that was not associated with dose, age, or prior therapy, including a prior SCT.
17
Relapse rates after SCT were mostly related to disease characteristics at SCT such as disease status at SCT and cytogenetics. Relapse rates were remarkably low in patients with MDS, most of them with excess of blasts and not given prior chemotherapy. The initial dosefinding study did find a lower relapse rate with higher treosulfan dose and thus recommended the 42 g/m 2 (FT14) for further study. 9 We were unable to confirm this dose effect on relapse rate in the current analysis. In all. LFS was better after FT14 than FT12 in the univariate analysis, but this was no longer evident after adjusting for patient characteristics. The data did not allow analysis of the dose effect in patient subsets, but based on this data we can suggest, that FT14, should be the standard, at least for standard-risk patients.
The current study shows a role for KIR ligand typing in determining outcome. Patients with C2C2 group ligands, had a lower rate of relapse and better LFS, than patients with C1C1 or C1C2. The ligand grouping had no impact on the rate of GVHD or NRM. This observations suggest that NK cells may be involved. transplants from an unrelated donor with at least one B haplotype was associated with less relapse and NRM and better outcome than from a donor with AA haplotypes. 40 Both centromeric and telomeric B motifs contributed to these effects, but best results were from donors with homozygous centromeric B motifs or with a higher B motif content. 41 Relapse protection was only seen in patients with at least one C1 epitope and mismatched HLA transplant, but not in C2C2 recipients. 42 This observation suggest that KIR2DL2-C1 interaction is the dominant cause of this effect. KIR2DL2 has stronger affinity for C1 than KIR2DL3 and also some cross reactivity with C2, thus may better license NK cells. 43 Venstrom et al. 44 showed an important role of donor KIR2DS1 in reducing relapse rates after unrelated donor SCT in AML. KIR2DS1 is the most known activating KIR that is specific to C2. The antileukemic effect was only seen in donors that were not C2C2. High levels of the C2 ligand in C2C2 donors causes KIR2DS1 expressing NK cells to become hyporesponsive. Thus patients with C2C2 having an HLAmatched unrelated donors had worse outcome and the authors suggest choosing a KIR2DS1 positive donor with a C mismatch (C1C2), to reduce the relapse risk in these patients. KIR3DS1 which is in genetic linkage disequilibrium with KIRDS1 had no effect on relapse but was associated with decreased mortality. Both these KIRs are telomeric rather than centromeric, and unlike the results of Cooley et al., this group showed an effect of specific activating KIR rather than the global effect of B-haplotypes. with reduced-intensity conditioning failed to confirm the association of C2 and relapse or the effect of activation KIR and B-haplotypes. 47 NK cell effects were seen mostly in SCT with T-cell depletion. T-cells in the graft may delay NK cell reconstitution, compete for cytokines and mask the beneficial effect by enhancing GVHD. 32, 48 In the current analysis the NK effect was also more evident in patient given ATG which results in partial T-cell depletion. NK cell effect was seen more after BM than after PBSC transplantation. 32 The source of NK cells after SCT may be from NK cells in the graft, as well as from NK cells that are produced early after SCT from donor stem cells. 49 Mega-dose stem cells can enhance NK cell maturation, while high NK cell dose in the graft may show an immediate benefit early after SCT.
It is not clear why in the current dataset of patients transplanted with treosulfan conditioning we have seen a dominant beneficial effect of C2C2. Treosulfan-based condition has been associated with a unique cytokine milieu that resulted in a lower rate of GVHD. 3, 7 This milieu may have supported NK cell activity, possibly by activating unlicensed NK cells in the graft. Only studies that will incorporate genetic, phenotypic, and functional assays of NK cell reconstitution after SCT with different regimens will be able to support these initial observations. If indeed confirmed, patients with C2C2, who are considered at high risk for relapse, in most studies, could be offered treosulfan-based conditioning.
